Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers

Inclusion Criteria: * Healthy adult male and female subjects, 18-65 years of age inclusive * BMI 18 to 32 kg/m2 inclusive * Female subjects must be surgically sterile or postmenopausal for the past year and have a negative urine pregnancy test. Male subjects and their partners of childbearing potential must be willing to use two methods of contraception, one of which must be a barrier method (e.g. condom) for up to 90 days after the last study drug administration. * Willing and able to remain in the clinical research unit as required by the protocol * Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements Exclusion Criteria: * History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease * History or presence of any disease, medical condition, or surgery, which may have an effect on drug absorption, metabolism, distribution, or excretion of the investigational product * Laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel, and urinalysis) that the investigator believes show clinically relevant significant abnormalities for the normal reference range * Any abnormality in the ECG (including QTc ≥450 msec) that in the opinion of the investigator increases the risk of participating in the study * History or presence of alcoholism or drug abuse within the year prior to dosing * Tobacco use, either current or within 3 months prior to dosing * Use of any prescription medications or herbal remedies within 14 days prior to dosing, or use of over-the-counter medications or vitamins within 7 days prior to dosing, unless approved by the Sponsor * Donation of whole blood within 56 days prior to the study * Plasma donation within 7 days prior to the study * Participation in an investigational device study or receipt of an investigational drug within 4 weeks prior to dosing * Positive urine test for drugs of abuse * Confirmed HIV, hepatitis B, or hepatitis C infection